sur ONWARD MEDICAL NV (isin : NL0015000HT4)
ONWARD Medical: 2024 Results and Progress to Start 2025
ONWARD Medical reported its 2024 financial results with notable progress. The company obtained FDA approval to market its ARC-EX system in the United States, generating its first sales through strategic partnerships. Ottobock invested in ONWARD, strengthening its financial visibility. The company expanded its technology portfolio by acquiring exclusive rights to a cutting-edge brain-machine interface.
Operating expenses increased slightly to €36.6 million, while the company recorded a net loss of €35.7 million for 2024. However, its net cash position doubled to €60 million. ONWARD is now focusing on commercial expansion and innovative clinical developments for 2025.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ONWARD MEDICAL NV